Series C Common Stock Purchase Warrant Sample Contracts
SERIES C COMMON STOCK PURCHASE WARRANT MOLECULIN BIOTECH, INC.Series C Common Stock Purchase Warrant • January 29th, 2025 • Moleculin Biotech, Inc. • Pharmaceutical preparations • New York
THIS SERIES C COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, [_____________] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the [Stockholder Approval Date]1 (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on the [____ (_)] year anniversary of the Initial Exercise Date (the “Termination Date”) but not thereafter, to subscribe for and purchase from Moleculin Biotech, Inc., a Delaware corporation (the “Company”), up to [______] shares of Common Stock (as subject to adjustment hereunder, the “Warrant Shares”). The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
SERIES C COMMON STOCK PURCHASE WARRANT MOLECULIN BIOTECH, INC.Series C Common Stock Purchase Warrant • February 10th, 2025 • Moleculin Biotech, Inc. • Pharmaceutical preparations • New York
THIS SERIES C COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, [_____________] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the Stockholder Approval Date (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on the [____ (_)] year anniversary of the Initial Exercise Date (the “Termination Date”) but not thereafter, to subscribe for and purchase from Moleculin Biotech, Inc., a Delaware corporation (the “Company”), up to [______] shares of Common Stock (as subject to adjustment hereunder, the “Warrant Shares”). The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
AMENDMENT NO. 2 TO SERIES C COMMON STOCK PURCHASE WARRANTSeries C Common Stock Purchase Warrant • August 5th, 2025 • Peraso Inc. • Semiconductors & related devices • New York
This AMENDMENT NO. 2 TO SERIES C COMMON STOCK PURCHASE WARRANT (this “Amendment No. 2”) is entered into as of August 4, 2025 (the “Effective Date”), by and between Peraso Inc., a Delaware corporation (the “Company”), and the holder (the “Holder”) of the Warrant (as defined below). Capitalized terms used and not otherwise defined herein shall have the respective meanings ascribed to them in the Warrant.
EVOKE PHARMA, INC. AMENDMENT TO SERIES C COMMON STOCK PURCHASE WARRANTSeries C Common Stock Purchase Warrant • September 27th, 2024 • Evoke Pharma Inc • Pharmaceutical preparations
This Amendment (this “Amendment”) is made as of ________, 2024 by and between Evoke Pharma, Inc., a Delaware corporation (the “Company”), and _______________ (the “Holder”), and constitutes an amendment to that certain Series C Common Stock Purchase Warrant (Warrant No.: C-[ ]), issued by the Company on February 13, 2024 (the “Series C Warrant”). Capitalized terms used but not otherwise defined in this Amendment shall have the meanings given to such terms in the Series C Warrant, as applicable.
Amendment to Series C Common Stock Purchase WarrantSeries C Common Stock Purchase Warrant • June 5th, 2009 • T3 Motion, Inc. • Motor vehicles & passenger car bodies
The Series C Common Stock Purchase Warrant (the “Warrant”) originally issued by T3 Motion, Inc., a Delaware corporation (the “Company”), and currently held by ___, (the “Holder”) granting to Holder the right to purchase up to ___ shares of Common Stock of the Company is hereby amended to provide as follows:
AMENDED AND RESTATED SERIES C COMMON STOCK PURCHASE WARRANT CYCLACEL PHARMACEUTICALS, inc.Series C Common Stock Purchase Warrant • September 2nd, 2025 • Cyclacel Pharmaceuticals, Inc. • Pharmaceutical preparations
THIS SERIES C COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on June 20, 2030 (the “Termination Date”) but not thereafter, to subscribe for and purchase from Cyclacel Pharmaceuticals, Inc., a Delaware corporation (the “Company”), up to 218,000 shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
AMENDMENT NO. 1 TO SERIES C COMMON STOCK PURCHASE WARRANTSeries C Common Stock Purchase Warrant • October 12th, 2022 • Neptune Wellness Solutions Inc. • Pharmaceutical preparations
This AMENDMENT NO. 1 TO SERIES C COMMON STOCK PURCHASE WARRANT (this “Amendment”) is entered into as of October 6, 2022, by and between Neptune Wellness Solutions Inc., a Quebec corporation (the “Company”), and Armistice Capital Master Fund Ltd. (the “Holder”).
SERIES C COMMON STOCK PURCHASE WARRANT REVIVA PHARMACEUTICALS HOLDINGS, INC.Series C Common Stock Purchase Warrant • June 26th, 2025 • Reviva Pharmaceuticals Holdings, Inc. • Pharmaceutical preparations
THIS SERIES C COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on June ___, 20301 (the “Termination Date”) but not thereafter, to subscribe for and purchase from Reviva Pharmaceuticals Holdings, Inc., a Delaware corporation (the “Company”), up to ______ shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
FORM OF FIRST AMENDMENT TO SERIES C COMMON STOCK PURCHASE WARRANTSeries C Common Stock Purchase Warrant • January 29th, 2009 • Pharma-Bio Serv, Inc. • Services-management consulting services
This FIRST AMENDMENT TO SERIES C COMMON STOCK PURCHASE WARRANT (“First Amendment”) is made and entered into as of the 23rd day of January, 2009, by and among PHARMA-BIO SERV, INC., formerly known as Lawrence Consulting Group, Inc., a Delaware corporation (“Pharma-Bio”) and [_____________] (“Holder”).
AMENDMENT TO SERIES C COMMON STOCK PURCHASE WARRANTSeries C Common Stock Purchase Warrant • May 2nd, 2025 • Peraso Inc. • Semiconductors & related devices • New York
This AMENDMENT TO SERIES C COMMON STOCK PURCHASE WARRANT (this “Amendment”) is entered into as of May __, 2025 (the “Effective Date”), by and between Peraso Inc., a Delaware corporation (the “Company”), and the holder (the “Holder”) of the Warrant (as defined below). Capitalized terms used and not otherwise defined herein shall have the respective meanings ascribed to them in the Warrant.